Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 7
2012 9
2013 3
2014 7
2015 9
2016 14
2017 10
2018 8
2019 10
2020 17
2021 23
2022 19
2023 17
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34675112

121 results

Results by year

Filters applied: . Clear all
Page 1
18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.
Burggraaff CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, Arens AIJ, de Keizer B, Heymans MW, van der Holt B, Wiegers SE, Pieplenbosch S, Boellaard R, de Vet HCW, Zijlstra JM; HOVON Imaging Working Group and the HOVON Lymphoma Working Group. Burggraaff CN, et al. J Nucl Med. 2022 Jul;63(7):1001-1007. doi: 10.2967/jnumed.121.262205. Epub 2021 Oct 21. J Nucl Med. 2022. PMID: 34675112 Free PMC article. Clinical Trial.
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani L. Zucca E, et al. Hematol Oncol. 2020 Dec;38(5):715-725. doi: 10.1002/hon.2805. Epub 2020 Oct 4. Hematol Oncol. 2020. PMID: 32947651
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.
Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F. Casasnovas RO, et al. Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12. Blood. 2017. PMID: 28701367 Free article. Clinical Trial.
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Hüttmann A, Schmitz C, Müller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Györke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCW. Eertink JJ, et al. Blood Adv. 2021 May 11;5(9):2375-2384. doi: 10.1182/bloodadvances.2021004467. Blood Adv. 2021. PMID: 33944897 Free PMC article.
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, Vera P, Bologna S, Brière J, Jais JP, Haioun C, Coiffier B, Morschhauser F; Groupe d'étude des lymphomes de l'adulte (GELA). Casasnovas RO, et al. Blood. 2011 Jul 7;118(1):37-43. doi: 10.1182/blood-2010-12-327767. Epub 2011 Apr 25. Blood. 2011. PMID: 21518924 Free article. Clinical Trial.
121 results